AR069752A1 - Composiciones que comprenden agonistas nicotinicos y su uso y kit - Google Patents
Composiciones que comprenden agonistas nicotinicos y su uso y kitInfo
- Publication number
- AR069752A1 AR069752A1 ARP080105141A ARP080105141A AR069752A1 AR 069752 A1 AR069752 A1 AR 069752A1 AR P080105141 A ARP080105141 A AR P080105141A AR P080105141 A ARP080105141 A AR P080105141A AR 069752 A1 AR069752 A1 AR 069752A1
- Authority
- AR
- Argentina
- Prior art keywords
- channel inhibitors
- agonists
- cotinine
- pharmaceutical composition
- sigma
- Prior art date
Links
- 239000000181 nicotinic agonist Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 12
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 3
- 229960002748 norepinephrine Drugs 0.000 abstract 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 3
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 abstract 2
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940121891 Dopamine receptor antagonist Drugs 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 2
- 108090000862 Ion Channels Proteins 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- FXFANIORDKRCCA-UHFFFAOYSA-N Norcotinine Chemical compound N1C(=O)CCC1C1=CC=CN=C1 FXFANIORDKRCCA-UHFFFAOYSA-N 0.000 abstract 2
- 229940127450 Opioid Agonists Drugs 0.000 abstract 2
- 102000004257 Potassium Channel Human genes 0.000 abstract 2
- 229940122490 Sigma receptor antagonist Drugs 0.000 abstract 2
- 229940127531 Sigma-1 Receptor Agonists Drugs 0.000 abstract 2
- 108010052164 Sodium Channels Proteins 0.000 abstract 2
- 102000018674 Sodium Channels Human genes 0.000 abstract 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 abstract 2
- 239000002876 beta blocker Substances 0.000 abstract 2
- 229940097320 beta blocking agent Drugs 0.000 abstract 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 2
- 229950006073 cotinine Drugs 0.000 abstract 2
- 238000000586 desensitisation Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
- 239000000472 muscarinic agonist Substances 0.000 abstract 2
- 239000002858 neurotransmitter agent Substances 0.000 abstract 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 2
- 229960002715 nicotine Drugs 0.000 abstract 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 abstract 2
- 229960005301 pentazocine Drugs 0.000 abstract 2
- 108020001213 potassium channel Proteins 0.000 abstract 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 abstract 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 abstract 1
- ZSTLCHCDLIUXJE-ZGBAEQJLSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride Chemical compound O.Cl.Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 ZSTLCHCDLIUXJE-ZGBAEQJLSA-N 0.000 abstract 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 abstract 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 abstract 1
- PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 abstract 1
- WUTYZMFRCNBCHQ-WPRPVWTQSA-N (2s,5s)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] Chemical compound C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-WPRPVWTQSA-N 0.000 abstract 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 abstract 1
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 abstract 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 abstract 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 abstract 1
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 abstract 1
- NUPUDYKEEJNZRG-LBPRGKRZSA-N 3-ethynyl-5-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CN1CCC[C@H]1C1=CN=CC(C#C)=C1 NUPUDYKEEJNZRG-LBPRGKRZSA-N 0.000 abstract 1
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 abstract 1
- XOKCJXZZNAUIQN-IENPIDJESA-N 3-hydroxycotinine Chemical compound C1C(O)C(=O)N(C)[C@@H]1C1=CC=CN=C1 XOKCJXZZNAUIQN-IENPIDJESA-N 0.000 abstract 1
- CXFZFEJJLNLOTA-UHFFFAOYSA-N 4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC#CCOC(=O)NC1=CC=CC(Cl)=C1 CXFZFEJJLNLOTA-UHFFFAOYSA-N 0.000 abstract 1
- BBNHNZGTKSWIHD-SNVBAGLBSA-N 5'-Hydroxycotinine Chemical compound CN1C(=O)CC[C@@]1(O)C1=CC=CN=C1 BBNHNZGTKSWIHD-SNVBAGLBSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 abstract 1
- -1 AF-150 Chemical compound 0.000 abstract 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 abstract 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 abstract 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 abstract 1
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 abstract 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract 1
- JUOSGGQXEBBCJB-UHFFFAOYSA-N Metanicotine Natural products CNCCC=CC1=CC=CN=C1 JUOSGGQXEBBCJB-UHFFFAOYSA-N 0.000 abstract 1
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 abstract 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 abstract 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 abstract 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 abstract 1
- 229960003305 alfaxalone Drugs 0.000 abstract 1
- 229950001297 altinicline Drugs 0.000 abstract 1
- 229960005260 amiodarone Drugs 0.000 abstract 1
- 229960002274 atenolol Drugs 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 abstract 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000623 carbamazepine Drugs 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229960001314 cevimeline Drugs 0.000 abstract 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
- 229960004606 clomipramine Drugs 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004170 clozapine Drugs 0.000 abstract 1
- 229960004126 codeine Drugs 0.000 abstract 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 abstract 1
- 229960004166 diltiazem Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001066 disopyramide Drugs 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 abstract 1
- 229960001393 dosulepin Drugs 0.000 abstract 1
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 abstract 1
- GEEFPQBPVBFCSD-XHNCKOQMSA-N epiboxidine Chemical compound O1N=C(C)C=C1[C@@H]1[C@H](N2)CC[C@H]2C1 GEEFPQBPVBFCSD-XHNCKOQMSA-N 0.000 abstract 1
- ZFOJLLQHJIXKHO-UHFFFAOYSA-N epiquinamide Natural products C1CCCC2C(NC(=O)C)CCCN21 ZFOJLLQHJIXKHO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000449 flecainide Drugs 0.000 abstract 1
- 229960003980 galantamine Drugs 0.000 abstract 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 abstract 1
- 229960001848 lamotrigine Drugs 0.000 abstract 1
- 229960004194 lidocaine Drugs 0.000 abstract 1
- 229960002813 lofepramine Drugs 0.000 abstract 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 abstract 1
- 229960002409 mepivacaine Drugs 0.000 abstract 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002237 metoprolol Drugs 0.000 abstract 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003404 mexiletine Drugs 0.000 abstract 1
- NCGLTZSBTFVVAW-KNXRZYMVSA-N minaxolone Chemical compound C1[C@@H](N(C)C)[C@@H]2[C@@]3(C)C[C@H](OCC)[C@@H](O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C NCGLTZSBTFVVAW-KNXRZYMVSA-N 0.000 abstract 1
- 229960004798 minaxolone Drugs 0.000 abstract 1
- ZFOJLLQHJIXKHO-GHMZBOCLSA-N n-[(1r,9ar)-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-yl]acetamide Chemical compound C1CCC[C@@H]2[C@H](NC(=O)C)CCCN21 ZFOJLLQHJIXKHO-GHMZBOCLSA-N 0.000 abstract 1
- 229960001158 nortriptyline Drugs 0.000 abstract 1
- 229960005290 opipramol Drugs 0.000 abstract 1
- 229960002036 phenytoin Drugs 0.000 abstract 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 abstract 1
- 229960000244 procainamide Drugs 0.000 abstract 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 abstract 1
- 229960000203 propafenone Drugs 0.000 abstract 1
- 229960003712 propranolol Drugs 0.000 abstract 1
- 229960002601 protriptyline Drugs 0.000 abstract 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 abstract 1
- 229960001404 quinidine Drugs 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- 229960002370 sotalol Drugs 0.000 abstract 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 abstract 1
- MKTAGSRKQIGEBH-SSDOTTSWSA-N tebanicline Chemical compound C1=NC(Cl)=CC=C1OC[C@@H]1NCC1 MKTAGSRKQIGEBH-SSDOTTSWSA-N 0.000 abstract 1
- 229960004605 timolol Drugs 0.000 abstract 1
- 229960002872 tocainide Drugs 0.000 abstract 1
- XUPZAARQDNSRJB-SJDTYFKWSA-N trans-dothiepin hydrochloride Chemical compound [Cl-].C1SC2=CC=CC=C2C(=C/CC[NH+](C)C)/C2=CC=CC=C21 XUPZAARQDNSRJB-SJDTYFKWSA-N 0.000 abstract 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 abstract 1
- 229960004751 varenicline Drugs 0.000 abstract 1
- 229960001722 verapamil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99016107P | 2007-11-26 | 2007-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069752A1 true AR069752A1 (es) | 2010-02-17 |
Family
ID=40380297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105141A AR069752A1 (es) | 2007-11-26 | 2008-11-26 | Composiciones que comprenden agonistas nicotinicos y su uso y kit |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8273731B2 (enExample) |
| EP (1) | EP2224917B1 (enExample) |
| JP (1) | JP5456687B2 (enExample) |
| KR (1) | KR101613742B1 (enExample) |
| CN (1) | CN101925352B (enExample) |
| AR (1) | AR069752A1 (enExample) |
| AU (1) | AU2008331102B2 (enExample) |
| BR (1) | BRPI0819911A2 (enExample) |
| CA (1) | CA2744736C (enExample) |
| CL (1) | CL2008003507A1 (enExample) |
| CY (1) | CY1119768T1 (enExample) |
| DK (1) | DK2224917T3 (enExample) |
| ES (1) | ES2642873T3 (enExample) |
| HR (1) | HRP20171476T1 (enExample) |
| HU (1) | HUE035105T2 (enExample) |
| LT (1) | LT2224917T (enExample) |
| MX (1) | MX2010005804A (enExample) |
| PL (1) | PL2224917T3 (enExample) |
| PT (1) | PT2224917T (enExample) |
| SI (1) | SI2224917T1 (enExample) |
| WO (1) | WO2009069126A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| JP2011530222A (ja) | 2008-08-01 | 2011-12-15 | ゾラン コーポレイション | 雑音除去のための統合時間フィルタを備えたビデオエンコーダ |
| US9801865B2 (en) * | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
| US8529914B2 (en) | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| EP2701681B1 (en) | 2011-04-29 | 2016-10-19 | Moberg Pharma AB | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
| EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| EP2882428B1 (en) | 2012-07-13 | 2019-01-16 | Pain Therapeutics, Inc. | A method of inhibiting tau phosphorylation |
| PL3777833T3 (pl) | 2014-03-13 | 2024-03-25 | Neuroderm Ltd. | Kompozycje inhibitorów dekarboksylazy dopa |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| WO2015183530A1 (en) * | 2014-05-29 | 2015-12-03 | Goodman Jory F | Nicotine derivatives and methods of use |
| WO2016042413A1 (en) * | 2014-09-18 | 2016-03-24 | Neuroderm, Ltd. | Opipramol patch |
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| CN112155255B (zh) | 2014-12-05 | 2025-10-28 | 尤尔实验室有限公司 | 校正剂量控制 |
| NZ746468A (en) | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| US10292977B2 (en) * | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| WO2017178897A2 (en) * | 2016-04-12 | 2017-10-19 | Arturo Solis Herrera | Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
| IL311984A (en) | 2016-07-07 | 2024-06-01 | Hughes Howard Med Inst | Modified ligand-gated ion channels and methods of use |
| KR20180058644A (ko) * | 2016-11-24 | 2018-06-01 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
| WO2018150276A2 (en) | 2017-02-16 | 2018-08-23 | Universidad San Sebastian | The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions |
| US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| CN111556751B (zh) * | 2017-11-10 | 2024-07-12 | 霍华休斯医学研究院 | 经修饰的配体门控的离子通道及使用方法 |
| US20230381195A1 (en) * | 2017-12-20 | 2023-11-30 | Akhil MEHRA | Methods and compositions for the treatment of traumatic brain injury (tbi) and related disorders |
| LU101519B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
| CN121015646A (zh) * | 2025-09-17 | 2025-11-28 | 湖北工业大学 | 一种药物组合物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5069094A (en) * | 1987-09-08 | 1991-12-03 | Birkestrand Orville J | Tube end finishing machine |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| FI945446A7 (fi) * | 1992-05-18 | 1995-01-18 | Pharmaco Behavioral Ass Inc | Kotiinin käyttö tupakan vieroitusoireyhtymän lievittämiseksi |
| JPH09262287A (ja) * | 1996-03-28 | 1997-10-07 | Terumo Corp | 薬液注入装置 |
| CA2279651A1 (en) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| CA2418135C (en) * | 2000-08-03 | 2011-09-20 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
| DE10134038A1 (de) | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| US20030119879A1 (en) * | 2001-10-15 | 2003-06-26 | Thomas Landh | Nicotine and chocolate compositions |
| US6852741B2 (en) * | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
| US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| WO2004056305A2 (en) * | 2002-12-18 | 2004-07-08 | Algorx | Administration of capsaicinoids |
| ITMI20030828A1 (it) | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione dell'opipramolo. |
| CA2538856C (en) * | 2003-10-10 | 2010-06-29 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
| US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
| WO2005115471A2 (en) | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
| US20060142349A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| US20080014252A1 (en) * | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
| CN101534833B (zh) | 2006-07-18 | 2013-03-13 | 贝塞斯达药理学联合有限责任公司 | 烟碱脱敏剂及选择、测试及使用它们的方法 |
| WO2008028903A2 (en) * | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
-
2008
- 2008-11-25 CL CL2008003507A patent/CL2008003507A1/es unknown
- 2008-11-26 LT LTEP08855517.2T patent/LT2224917T/lt unknown
- 2008-11-26 KR KR1020107014088A patent/KR101613742B1/ko not_active Expired - Fee Related
- 2008-11-26 CA CA2744736A patent/CA2744736C/en not_active Expired - Fee Related
- 2008-11-26 AR ARP080105141A patent/AR069752A1/es not_active Application Discontinuation
- 2008-11-26 CN CN200880126096.9A patent/CN101925352B/zh not_active Expired - Fee Related
- 2008-11-26 JP JP2010534598A patent/JP5456687B2/ja not_active Expired - Fee Related
- 2008-11-26 ES ES08855517.2T patent/ES2642873T3/es active Active
- 2008-11-26 PT PT88555172T patent/PT2224917T/pt unknown
- 2008-11-26 BR BRPI0819911A patent/BRPI0819911A2/pt not_active IP Right Cessation
- 2008-11-26 WO PCT/IL2008/001546 patent/WO2009069126A1/en not_active Ceased
- 2008-11-26 SI SI200831872T patent/SI2224917T1/sl unknown
- 2008-11-26 PL PL08855517T patent/PL2224917T3/pl unknown
- 2008-11-26 HR HRP20171476TT patent/HRP20171476T1/hr unknown
- 2008-11-26 AU AU2008331102A patent/AU2008331102B2/en not_active Ceased
- 2008-11-26 EP EP08855517.2A patent/EP2224917B1/en not_active Not-in-force
- 2008-11-26 DK DK08855517.2T patent/DK2224917T3/en active
- 2008-11-26 HU HUE08855517A patent/HUE035105T2/en unknown
- 2008-11-26 MX MX2010005804A patent/MX2010005804A/es active IP Right Grant
- 2008-11-26 US US12/323,779 patent/US8273731B2/en not_active Expired - Fee Related
-
2012
- 2012-08-24 US US13/593,911 patent/US8921356B2/en not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,660 patent/US20150306109A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,752 patent/US20170128432A1/en not_active Abandoned
-
2017
- 2017-10-04 CY CY20171101027T patent/CY1119768T1/el unknown
- 2017-11-30 US US15/827,293 patent/US20180303818A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20171476T1 (hr) | 2017-12-15 |
| CL2008003507A1 (es) | 2009-11-27 |
| DK2224917T3 (en) | 2017-10-16 |
| CA2744736C (en) | 2015-06-09 |
| US20180303818A1 (en) | 2018-10-25 |
| US8273731B2 (en) | 2012-09-25 |
| ES2642873T3 (es) | 2017-11-20 |
| JP2011504490A (ja) | 2011-02-10 |
| US20150306109A1 (en) | 2015-10-29 |
| US20170128432A1 (en) | 2017-05-11 |
| US20090149446A1 (en) | 2009-06-11 |
| BRPI0819911A2 (pt) | 2017-06-13 |
| EP2224917A1 (en) | 2010-09-08 |
| JP5456687B2 (ja) | 2014-04-02 |
| SI2224917T1 (sl) | 2017-12-29 |
| CA2744736A1 (en) | 2009-06-04 |
| WO2009069126A1 (en) | 2009-06-04 |
| KR20100105841A (ko) | 2010-09-30 |
| KR101613742B1 (ko) | 2016-04-19 |
| US20130172321A1 (en) | 2013-07-04 |
| LT2224917T (lt) | 2017-12-27 |
| US8921356B2 (en) | 2014-12-30 |
| EP2224917B1 (en) | 2017-07-05 |
| MX2010005804A (es) | 2010-11-30 |
| CY1119768T1 (el) | 2018-06-27 |
| HUE035105T2 (en) | 2018-05-02 |
| AU2008331102A1 (en) | 2009-06-04 |
| CN101925352A (zh) | 2010-12-22 |
| PL2224917T3 (pl) | 2018-02-28 |
| AU2008331102B2 (en) | 2014-04-10 |
| PT2224917T (pt) | 2017-10-17 |
| CN101925352B (zh) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6280476A2 (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
| AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
| CL2008000212A1 (es) | Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre | |
| HN2010002491A (es) | Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina | |
| ECSP066520A (es) | Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso | |
| EP2054411A4 (en) | NEW COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY SALTS SUCH AS VANILLOIDREZEPTORANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ECSP056148A (es) | Compuestos inmunosupresores y composiciones | |
| DOP2009000133A (es) | Derivados de indol como agonistas de los receptores s1p1 | |
| EA200900606A1 (ru) | Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов | |
| BR0206968A (pt) | Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como antagonistas receptores de quimiocina cxc | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| CR10138A (es) | 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina | |
| PA8836101A1 (es) | Inhibidores alfa7 nicotínicos del receptor de acetilcolina | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| EA200970085A1 (ru) | Замещённые n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения | |
| PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
| CO6410303A2 (es) | Nicotinamidas sustituidas como moduladores de kcnq2/3 | |
| UY29322A1 (es) | Inhibidores de cxcr2 | |
| AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
| CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
| CL2008001671A1 (es) | Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes. | |
| AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
| WO2009013212A3 (en) | Dual modulators of 5-ht2a and d3 receptors | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| CL2009000085A1 (es) | Compuestos derivados de sulfonamida sustituida, modulares de receptores de bradiquinina; proceso para su preparacion; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |